- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07412704
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
-
Leuven, Belgium, 3000
- Not yet recruiting
- Local Institution - 0049
-
Contact:
- Site 0049
-
-
Flanders
-
Merksem, Flanders, Belgium, 2170
- Not yet recruiting
- Local Institution - 0048
-
Contact:
- Site 0048
-
-
-
-
Goiás
-
Aparecida de Goiânia, Goiás, Brazil, 74935-530
- Not yet recruiting
- Local Institution - 0083
-
Contact:
- Site 0083
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90050-010
- Not yet recruiting
- Local Institution - 0033
-
Contact:
- Site 0033
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13271-130
- Not yet recruiting
- Local Institution - 0082
-
Contact:
- Site 0082
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100091
- Not yet recruiting
- Local Institution - 0006
-
Contact:
- Site 0006
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510260
- Not yet recruiting
- Local Institution - 0080
-
Contact:
- Site 0080
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Not yet recruiting
- Local Institution - 0010
-
Contact:
- Site 0010
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Not yet recruiting
- Local Institution - 0007
-
Contact:
- Site 0007
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Not yet recruiting
- Local Institution - 0020
-
Contact:
- Site 0020
-
Shanghai, Shanghai Municipality, China, 200127
- Not yet recruiting
- Local Institution - 0001
-
Contact:
- Site 0001
-
-
-
-
-
Berlin, Germany, 10117
- Recruiting
- Charité Research Organisation
-
Contact:
- Stanislav Ignatenko, Site 0022
- Phone Number: 4930450539200
-
Cologne, Germany, 50937
- Not yet recruiting
- Local Institution - 0021
-
Contact:
- Site 0021
-
Herne, Germany, 44649
- Recruiting
- Rheumazentrum Ruhrgebiet
-
Contact:
- Xenofon Baraliakos, Site 0028
- Phone Number: +492325592709
-
Sendenhorst, Germany, 48324
- Recruiting
- St. Josef-Stift Sendenhorst
-
Contact:
- Peter Korsten, Site 0056
- Phone Number: +495513913065117
-
-
Bavaria
-
München, Bavaria, Germany, 81377
- Not yet recruiting
- Local Institution - 0040
-
Contact:
- Site 0040
-
-
-
-
-
Roma, Italy, 00168
- Recruiting
- Fondazione Policlinico Gemelli IRCCS
-
Contact:
- MARIA ANTONIETTA D'AGOSTINO, Site 0017
- Phone Number: +393495458711
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Recruiting
- Istituto Clinico Humanitas
-
Contact:
- Elisa Gremese, Site 0019
- Phone Number: +393271418439
-
-
-
-
-
México, Mexico, 14080
- Not yet recruiting
- Local Institution - 0053
-
Contact:
- Site 0053
-
-
-
-
Masovian Voivodeship
-
Józefów, Masovian Voivodeship, Poland, 05-410
- Not yet recruiting
- Local Institution - 0023
-
Contact:
- Site 0023
-
-
-
-
-
Córdoba, Spain, 14004
- Recruiting
- Hospital Universitario Reina Sofia
-
Contact:
- ALEJANDRO ESCUDERO, Site 0058
- Phone Number: 957011631
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Spain, 15006
- Recruiting
- CHUAC-Complejo Hospitalario Universitario A Coruña
-
Contact:
- Francisco Javier Blanco Garcia, Site 0039
- Phone Number: 981176399
-
-
-
-
-
Bern, Switzerland, 3010
- Recruiting
- Universitaetsspital Bern - Inselspital
-
Contact:
- Burkhard Moeller, Site 0037
- Phone Number: 0000000000
-
Geneva, Switzerland, 1211
- Recruiting
- Hôpitaux Universitaire de Genève
-
Contact:
- Kim Lauper, Site 0027
- Phone Number: +41 (0)22 372 36 78
-
-
-
-
-
Kyiv, Ukraine, 01135
- Not yet recruiting
- Local Institution - 0064
-
Contact:
- Site 0064
-
Ternopil, Ukraine, 46002
- Not yet recruiting
- Local Institution - 0061
-
Contact:
- Site 0061
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76008
- Not yet recruiting
- Local Institution - 0060
-
Contact:
- Site 0060
-
-
Poltava Oblast
-
Poltava, Poltava Oblast, Ukraine, 36011
- Not yet recruiting
- Local Institution - 0063
-
Contact:
- Site 0063
-
-
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- UCSD - Altman Clinical and Translational Research Institute (ACTRI)
-
Contact:
- DoQuyen Huynh, Site 0068
- Phone Number: 858-657-6110
-
Loma Linda, California, United States, 92354
- Withdrawn
- Local Institution - 0070
-
Palo Alto, California, United States, 94304-2210
- Not yet recruiting
- Local Institution - 0069
-
Contact:
- Site 0069
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Not yet recruiting
- Local Institution - 0050
-
Contact:
- Site 0050
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
Contact:
- Richard Nash, Site 0067
- Phone Number: 303-981-2305
-
-
Florida
-
South Miami, Florida, United States, 33143
- Not yet recruiting
- Local Institution - 0055
-
Contact:
- Site 0055
-
-
New York
-
New York, New York, United States, 10016
- Not yet recruiting
- Local Institution - 0081
-
Contact:
- Site 0081
-
New York, New York, United States, 10029
- Not yet recruiting
- Local Institution - 0079
-
Contact:
- Site 0079
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Not yet recruiting
- Local Institution - 0066
-
Contact:
- Site 0066
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Withdrawn
- Local Institution - 0071
-
-
Texas
-
DeSoto, Texas, United States, 75115
- Withdrawn
- Local Institution - 0051
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.
Exclusion Criteria
- Juvenile arthritis or onset of inflammatory arthritis before age 18.
- Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.
- Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cohort A1
|
Specified dose on specified days |
|
Experimental: Cohort A2
|
Specified dose on specified days |
|
Experimental: Cohort A3
|
Specified dose on specified days |
|
Experimental: Cohort A4
|
Specified dose on specified days |
|
Experimental: Cohort A5
|
Specified dose on specified days |
|
Experimental: Cohort A6
|
Specified dose on specified days |
|
Experimental: Cohort A7
|
Specified dose on specified days |
|
Experimental: Cohort A8
|
Specified dose on specified days |
|
Experimental: Cohort B1
|
Specified dose on specified days |
|
Experimental: Cohort B2
|
Specified dose on specified days |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Number of participants with Serious Adverse Events (SAEs)
Time Frame: Up to Week 54
|
Up to Week 54
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed concentration (Cmax)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Time of maximum observed concentration (Tmax)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Apparent terminal serum half-life (T-HALF)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Apparent total body clearance (CLT/F)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Apparent volume of distribution of terminal phase (Vz/F)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in numbers and fractions of B cells
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in immunoglobulin G (igG) levels
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in igM levels
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in igE levels
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in igD levels
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in igA levels
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Number of participants with anti-drug antibody (ADA)
Time Frame: Up to Week 54
|
Up to Week 54
|
|
Change from baseline in disease activity score 28-C-reactive protein (DAS28-CRP)
Time Frame: At Week 12
|
At Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM062-0001
- 2025-520666-22 (Other Identifier: EU CTR)
- U1111-1317-6393 (Other Identifier: WHO)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD Sharing Time Frame
See Plan Description
IPD Sharing Access Criteria
See Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.